Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings are โน41.89 Billion. , an increase over its 2023 earnings that were of โน1.335 Trillion. The earnings displayed on this page is the company's Pretax Income.